Obstructive Sleep ApneaNCT05980936
Screening for Obstructive Sleep Apnea in Medical Patients
An observational study of Obstructive Sleep Apnea, run by Jordan Collaborating Cardiology Group at 2 sites in Jordan.
Trial summary
Obstructive sleep apnea (OSA) is highly prevalent in the general population and is associated with multiple adverse cardiovascular consequences. Screening for OSA is recommended in those with typical symptoms, such as daytime sleepiness, loud snoring, or abrupt awakenings with gasping or choking. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obstructive Sleep Apnea
- What is being tested?
- Screening for obstructive sleep apnea
- How many people
- 0 participants
- Where
- 2 sitesJordan
- Study dates
- 15 Oct 2023to 22 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients without known OSA who are admitted to the general medical ward will be Screened for signs and symptoms of OSA by answering the questions that have the statement :Do you have...?". The symptoms include snoring, day time somnolesce, sudden chocking or gasping during sleep..
Who may be able to join
- Willing to sign an informed consent
- Patient is admitted to the medical ward in a tertiary hospital
Who cannot join
- Patients known to have obstructive sleep apnea.
- Patients younger than 18 years of age
Trial locations and contacts
2 sites in 1 country.
About this study
Official title: Screening for Obstructive Sleep Apnea in the General Medical Ward in Tertiary Care Centers in the Middle East
Obstructive sleep apnea (OSA) is highly prevalent in the general population and is associated with multiple adverse cardiovascular consequences.
Screening for OSA is recommended in those with typical symptoms, such as daytime sleepiness, loud snoring, or abrupt awakenings with gasping or choking. Patients admitted to the general medical wards with these symptoms will be evaluated for the possibility of having OSA.
Read the detailed description
Obstructive sleep apnea (OSA) is a disease that is highly prevalent in all communities and is associated with adverse cardiovascular events.
Screening for OSA is recommended in men and women who have the typical symptoms, including snoring, daytime sleepiness, or abrupt awakenings with choking or gasping.
OSA screening is also recommended for those with resistant hypertension, bradyarrhythmias, and atrial fibrillation.
Heart failure patients should also be screened for OSA. It is very important to increase the use of OSA screening especially in patients admitted to the medical floor in tertiary care hospitals. No study has evaluated this topic in the Middle East in the past.
- Conditions
- Obstructive Sleep Apnea
- Being tested
- Screening for obstructive sleep apnea
- Keywords
- Obstructive sleep apnea, Symptomatology, Middle East
- Medical subject headings
- Sleep Apnea, Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Screening for obstructive sleep apneaOther
Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants who are found to have obstructive sleep apnea
Those who are found to have symptoms of OSA will be referred for further evaluation to get the final diagnosis of OSA
Measured: From date of study enrollment until the date of first documented diagnosis of obstructive sleep apnea, assessed up to 4 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2023
- Study start15 Oct 2023
- Primary completion15 Feb 2025
- Study completion22 Feb 2025
Why it stopped: no patients found
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obstructive Sleep ApneaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jordan Collaborating Cardiology Group
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05980936
- Sponsor's protocol ID
- IH.OSAScrnng.2023/2
- Status last verified
- Feb 2025
- First submitted
- 20 Jul 2023
- Last updated
- 25 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening for Obstructive Sleep Apnea in the General Medical Ward in Tertiary Care Centers in the Middle East
- ClinicalTrials.gov ID
- NCT05980936
- Acronym / sponsor ID
- IH.OSAScrnng.2023/2
- Conditions
- Obstructive Sleep Apnea
- Keywords
- Obstructive sleep apnea, Symptomatology, Middle East
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: no patients found
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Jordan Collaborating Cardiology GroupUniversity, hospital or other
- Study start
- 15 Oct 2023 (actual)
- Primary completion
- 15 Feb 2025 (actual)
- Study completion
- 22 Feb 2025 (actual)
- First posted
- 8 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obstructive sleep apnea (OSA) is highly prevalent in the general population and is associated with multiple adverse cardiovascular consequences.
Screening for OSA is recommended in those with typical symptoms, such as daytime sleepiness, loud snoring, or abrupt awakenings with gasping or choking. Patients admitted to the general medical wards with these symptoms will be evaluated for the possibility of having OSA.
Detailed description
Obstructive sleep apnea (OSA) is a disease that is highly prevalent in all communities and is associated with adverse cardiovascular events.
Screening for OSA is recommended in men and women who have the typical symptoms, including snoring, daytime sleepiness, or abrupt awakenings with choking or gasping.
OSA screening is also recommended for those with resistant hypertension, bradyarrhythmias, and atrial fibrillation.
Heart failure patients should also be screened for OSA. It is very important to increase the use of OSA screening especially in patients admitted to the medical floor in tertiary care hospitals. No study has evaluated this topic in the Middle East in the past.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients without known OSA who are admitted to the general medical ward will be Screened for signs and symptoms of OSA by answering the questions that have the statement :Do you have...?". The symptoms include snoring, day time somnolesce, sudden chocking or gasping during sleep..
Key inclusion criteria (2 listed)
- Willing to sign an informed consent
- Patient is admitted to the medical ward in a tertiary hospital
Key exclusion criteria (2 listed)
- Patients known to have obstructive sleep apnea.
- Patients younger than 18 years of age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Screening for obstructive sleep apneaPatient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep | Other | – |
Primary outcome
Number of Participants who are found to have obstructive sleep apnea
Time frame: From date of study enrollment until the date of first documented diagnosis of obstructive sleep apnea, assessed up to 4 weeks.
Those who are found to have symptoms of OSA will be referred for further evaluation to get the final diagnosis of OSA
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2025.
Related trials for Obstructive Sleep Apnea
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
Recruiting
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 1/2
DRonabinol Treatment of OSA
Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obstructive Sleep Apnea, run by Jordan Collaborating Cardiology Group at 2 sites in Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 25 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants who are found to have obstructive sleep apnea (time frame: From date of study enrollment until the date of first documented diagnosis of obstructive sleep apnea, assessed up to 4 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2025.